The efficacy of mirabegron for the relief of ureteral stent-related symptoms

Hideo Otsuki, Tomoya Yamasaki, Shunsuke Hori, Hiroshi Aoki, Takeo Kosaka, Shinya Uehara, Kei Fujio

Research output: Contribution to journalArticle

Abstract

To investigate the efficacy of mirabegron for lower urinary tract symptoms in patients with an indwelling ureteral stent after ureterorenoscopic lithotripsy. This was a prospective follow-up study of 76 patients with stent-related symptoms (SRSs). Patients with upper urinary calculi who were pre-stented for > 2 weeks before lithotripsy were examined for the presence of SRSs by tests including the International Prostate Symptom Score (IPSS), OAB Symptom Score (OABSS), and urinary bother and pain measured by a Visual Analogue Scale (VAS) before lithotripsy. Mirabegron (50 mg/day) was prescribed post-lithotripsy for 2 weeks. SRSs were assessed at the time of stent removal. The IPSS scores improved significantly from 16.2 to 14.3 (p<0.001) and the IPSS-QoL scores decreased significantly from 5.0 to 4.6 (p=0.012). The OABSS scores improved significantly from 7.7 to 6.8 (p=0.006), and the urinary urgency scores (OABSS-Q3) decreased significantly from 3.24 to 2.68 (p<0.001). The number of nocturia episodes decreased significantly from 2.5 to 2.2 (p=0.045). Urinary bother and pain assessed by the VAS declined from 4.2 and 3.1 to 3.8 (p=0.15) and 2.5 (p=0.075), respectively. Mirabegron significantly improved SRSs and the number of nocturia episodes due to a ureteral stent.

Original languageEnglish
Pages (from-to)145-150
Number of pages6
JournalActa Medica Okayama
Volume74
Issue number2
Publication statusPublished - 2020

Keywords

  • Mirabegron
  • Overactive bladder
  • Stent-related symptoms
  • Ureteral stent
  • Ureterorenoscopic lithotripsy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'The efficacy of mirabegron for the relief of ureteral stent-related symptoms'. Together they form a unique fingerprint.

  • Cite this

    Otsuki, H., Yamasaki, T., Hori, S., Aoki, H., Kosaka, T., Uehara, S., & Fujio, K. (2020). The efficacy of mirabegron for the relief of ureteral stent-related symptoms. Acta Medica Okayama, 74(2), 145-150.